MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer
Abstract
No abstract available.
Image: Tufts Medical Center Teddy Bear (Formerly F.A.O. Schwartz Teddy Bear). Boston, MA, USA.
Downloads
References
http://www.marketwatch.com/story/merrimack-pharmaceuticals-announces-mm-398-achieves-primary-endpoint-of-overall-survival-in-phase-3-trial-in-post-gemcitabine-metastatic-pancreatic-cancer-2014-05-01 (last assessed May 06, 2014)
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 16.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 May 12; 364(19):1817-25.
Saif MW, Chabot J. Chemotherapy: Metastatic pancreatic cancer: is FOLFIRINOX the new standard? Nat Rev Clin Oncol 2011 Jul 5; 8(8):452-3.
Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011; 47: 1676-81.
Copyright (c) 2014 Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.